Metyloergometryna: interakcje

Do not use almotriptan tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT 1 agonist, e.g., another triptan ( 4.5 , 4.6 ) (etykieta leku Almotryptan, Przeciwwskazania)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Ergot derivatives: dihydroergotamine ergotamine methylergonovine ↑ dihydroergotamine ↑ ergotamine ↑ methylergonovine Concomitant administration with dihydroergotamine, ergotamine or methylergonovine is not recommended. (etykieta leku Biktegrawir + emtrycytabina + alafenamid tenofowiru, Interakcje z innymi lekami)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3)]. (etykieta leku Bupiwakaina, Ostrzeżenia i środki ostrożności)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ] . (etykieta leku Bupiwakaina + adrenalina, Ostrzeżenia i środki ostrożności)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur. (etykieta leku Chloroprokaina, Ostrzeżenia)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

• Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 (5-HT 1 ) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1) ] . (etykieta leku Eletryptan, Przeciwwskazania)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1 , 7.2) ]. (etykieta leku Frowatryptan, Przeciwwskazania)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ]. (etykieta leku Lidokaina + adrenalina, Ostrzeżenia i środki ostrożności)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. (etykieta leku Mepiwakaina, Ostrzeżenia)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

…Ischemic bowel disease [see Warnings and Precautions (5.5)] Uncontrolled hypertension [see Warnings and Precautions (5.8)] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan tablets (angioedema… (etykieta leku Naratryptan, Przeciwwskazania)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible. (etykieta leku Nitrogliceryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (etykieta leku Ryzatryptan, Przeciwwskazania)

…Precautions (5.5)] • Ischemic bowel disease [see Warnings and Precautions (5.5)] • Uncontrolled hypertension [see Warnings and Precautions (5.8)] • Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine 1 (5-HT 1 ) agonist [see Drug Interactions (7.1,… (etykieta leku Sumatryptan, Przeciwwskazania)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

…bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (etykieta leku Zolmitryptan, Przeciwwskazania)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

…drugs Tricyclic antidepressants Angiotensin, aldosterone Atropine Steroids, such as hydrocortisone Norepinephrine transporter inhibitors, such as atomoxetine Ergot alkaloids, such as methylergonovine maleate 7.2 Interactions that Antagonize the Pressor Effect The increasing blood pressure effect of BIORPHEN is decreased in patients receiving: α-adrenergic antagonists… (etykieta leku Fenylefryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (etykieta leku Lidokaina, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 Substrates Refer to the Prescribing Information for a CYP3A substrate where minimal concentration changes may lead to serious adverse reactions (e.g. rivaroxaban, calcineurin inhibitors, ergot derivatives, tyrosine kinase inhibitors) for the recommended dosage modification and/or monitoring. (etykieta leku Prymachina, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Coronary artery disease Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm. (etykieta leku Metyloergometryna, Ostrzeżenia)

Drugs antagonizing pressor effects of epinephrine α-blockers, such as phentolamine Vasodilators, such as nitrates Diuretics Antihypertensives Ergot alkaloids Drugs potentiating pressor effects of epinephrine • Sympathomimetics • β-blockers, such as propranolol • Tricyclic anti-depressants • Monoamine oxidase (MAO) inhibitors • Catechol-O-methyl transferase (COMT)… (etykieta leku Adrenalina, Interakcje z innymi lekami)

Drug Interactions CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of… (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Pressor Effect with Concomitant Oxytocic Drugs Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine) [ see Drug Interactions (7) ]. (etykieta leku Efedryna, Ostrzeżenia i środki ostrożności)

Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Drug Interactions CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of… (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (etykieta leku Metyloergometryna, Ostrzeżenia)

Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, and pleural thickening have been reported in some patients treated with ergot derived dopaminergic agents. (etykieta leku Karbidopa + lewodopa + entakapon, Ostrzeżenia i środki ostrożności)

Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in patients treated with ergot-derived dopaminergic agents. (etykieta leku Pramipeksol, Ostrzeżenia i środki ostrożności)

Concurrent administration of vasopressor drugs and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (etykieta leku Prylokaina + adrenalina, Interakcje z innymi lekami)

Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents. (etykieta leku Ropinirol, Ostrzeżenia i środki ostrożności)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (etykieta leku Metyloergometryna, Ostrzeżenia)